Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its ...

WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year

Related Keywords

United Kingdom ,United States ,Americans ,Luis Sanay ,Jeffreym Dayno ,Epygenix Therapeutics Inc ,Exchange Commission ,Epygenix Company Presentation ,Share Repurchase Program ,European Union ,European Medicines Agency ,Harmony Biosciences Holdings Inc ,Drug Administration ,Paragon Biosciences ,Nasdaq ,Net Revenue ,First Quarter ,New Drug Application ,Idiopathic Hypersomnia Planned ,Second Half ,Track Toward Pediatric Exclusivity ,Pediatric Narcolepsy ,Franchise Revenue Potential Extended Beyond ,Next Generation Formulations ,Reports Positive Pharmacokinetic Data ,Next Generation Formulation ,Leadership Position ,Highly Potent ,Selective Oral ,Epygenix Therapeutics ,Product Revenue Guidance ,Held Today ,Biosciences Holdings ,Chief Executive Officer ,Franchise Highlights ,Idiopathic Hypersomnia ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Operating Expenses ,Product Revenue ,Call Today ,Full Prescribing Information ,Harmony Biosciences ,United States Food ,Dravet Syndrome ,Gastaut Syndrome ,Plymouth Meeting ,Private Securities Litigation Reform Act ,Bioprojet Soci ,Civile De Recherche ,Annual Report ,Biosciences Investor Contact ,Biosciences Media Contact ,Region ,